Biomolecular Life Holdings, Inc. (BIOM) Stock Price & Analysis
Biomolecular Life Holdings, Inc. (BIOM) closed at USD 0.91 on Thursday, October 22, 2026, up 12.35% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.81; the Oct 22, 2026 session ranged USD 0.91–0.91 on volume of 111 shares. Market capitalization is $1.06M, with a 52-week range of USD 0.03–2.25 (OID). Source: Nexqual, retrieved October 24, 2026 at 02:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BIOM.md
Key facts (BIOM)
- Last four reported quarters (through Sep 30, 2015): revenue $0K, net income -$4.3M (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -11.0% vs S&P 500 +13.4%; 5Y -98.0% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BIOM)
| USD | FY2013 | FY2014 | TTM |
|---|---|---|---|
| Revenue | $0K | $0K | $0K |
| Operating income | -$3.9M | -$4.1M | -$2.7M |
| Net income | -$7.4M | -$6.2M | -$4.3M |
| EPS (diluted) | -$18200.00 | -$4400.00 | — |
| Free cash flow | -$1.0M | -$1.9M | — |
| Cash + short-term investments | $714K | $34K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2015) (BIOM)
Earnings yield -406.67%
Analysts (BIOM)
Consensus None.
Total return (dividends reinvested) (BIOM)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -11.0% | -98.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -11.1% | -54.4% |
| Volatility (annualized) | 633.5% | 376.9% |
| Max drawdown | -98.7% (Oct 2025→Jul 2026) | -99.9% (Oct 2021→Jul 2026) |
BIOM suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Company | “promissory note and warrant purchase agreement with MDC, pursuant to which MDC provided us $50,000 in cash.” |
| Partner | Fund | “19, 2015, we exercised our right to issue a put notice in the amount of $25,000 under our agreement with Dutchess Opportunity Fund” |
| Partner | Ambiopharm | “We do not currently have a contract or an exclusivity agreement with Ambiopharm.” |
| Partner | DMBM | “On February 15, 2013, we entered into a debenture purchase agreement with DMBM, Inc. whereby DMBM was obligated” |
| Partner | DW Odell Company | “promissory note and warrant purchase agreement with DW Odell Company, LLC, pursuant to which DW Odell is obligated to provide us” |
| Partner | Dutchess Opportunity Fund II | “September 4, 2014 and February 4, 2015, we entered into an investment agreement with Dutchess Opportunity Fund II L.P. where Dutchess” |
Quoted from the company's 10-K filed Apr 15, 2015.
BIOM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Jun 2012) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2012) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 02:21 UTC)
| Price | USD 0.91 |
|---|---|
| Change | ▲ 12.35% (up) |
| Previous Close | USD 0.81 |
| Open | USD 0.91 |
| Day Range | USD 0.91 – 0.91 |
| 52-Week Range | USD 0.03 – 2.25 |
| Volume | 111 shares |
| Market Cap | $1.06M |
| Exchange | OID |
Technical Analysis (BIOM)
Nexqual's technical model rates BIOM "STRONG BUY" based on 5 bullish and 0 bearish signals across 126 daily candles, as of October 24, 2026 at 02:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.69 (neutral) |
| vs SMA50 | Above (USD 0.58) |
| MACD | 0.1 (positive) |
Analyst Ratings (BIOM)
Wall Street analysts rate BIOM "None", per Nexqual as of October 24, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|
Earnings (BIOM)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2011-12-31 | USD 0 vs est 0 ▲ beat |
| 2011-09-30 | USD 0 vs est 0 ▲ beat |
| 2011-06-30 | USD 0 vs est 0 ▲ beat |
| 2011-03-31 | USD 0 vs est 0 ▲ beat |
Source: Nexqual, October 24, 2026 at 02:21 UTC.
Financials & Fundamentals (BIOM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0 |
| Total Debt | $512,404 |
Source: Nexqual, October 24, 2026 at 02:21 UTC.
Financial Health Score (BIOM)
Nexqual rates Biomolecular Life Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 02:21 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$61K (TTM) |
| Efficiency | Mixed — No data |
Ownership (BIOM)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 1.16M |
Source: Nexqual, October 24, 2026 at 02:21 UTC.
Leadership (BIOM)
Biomolecular Life Holdings, Inc. is led by Jessika Contreras, President, CEO, Secretary, Treasurer & Director, per Nexqual as of October 24, 2026 at 02:21 UTC.
| President, CEO, Secretary, Treasurer & Director | Jessika Contreras |
|---|
From Biomolecular Life Holdings, Inc.'s Latest SEC 10-K Filing (filed 2015-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- As there are over 200 million possible combinations of approved and development-stage oncological drugs, not including the hundreds of MDT oncological agents patented (Nature Biotechnology, Vol. 30 No 7 July 2012), it is more relevant to discuss the competition that may be faced by the sorafenib/hydroxychloroquine, or HCQ, treatment in an FDA phase I study. initiated, ongoing, and completed, involving a sorafenib combination treatment.
- We take measures to protect our proprietary know-how, technologies, and confidential data, including requiring all employees, consultants and customers to enter into confidentiality agreements.
Partnerships
- However, if we do, we must pay additional sublicense royalties based on when we enter into the sublicense, as specified below: last patent covered by it expires. exclusive license agreement with the University of Colorado granting us rights to patents, patent applications, and technologies developed by Dr.
- We do not currently have a contract or an exclusivity agreement with Ambiopharm.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KCHV | Kochav Defense Acquisition Corp | USD 10.51 | ▼ 0.1% |
| FVAV | Fortress Value Acquisition Corp | USD 10.04 | ▼ 0.3% |
| TACH | Titan Acquisition Corp. | USD 10.55 | ▲ 0.09% |
| ALUB | Alussa Energy Acquisition Corp. | USD 10.15 | ▲ 0.2% |
| OIM | OneIM Acquisition Corp. | USD 10.11 | ▲ 0.05% |
| FCRS | FutureCrest Acquisition Corp. | USD 10.21 | ▲ 0.1% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 02:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt